We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine Derivatives.
- Authors
Ali, Rania S.; Saad, Hosam A.; Belmont, Philippe
- Abstract
A novel fused system with three or four fused rings—pyridazino[3′,4′:5,6][1,2,4]triazino[4,3-<italic>b</italic>][1,2,4,5]tetrazine and pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-<italic>b</italic>]pyrimido[4,5-<italic>e</italic>][1,3,4]thiadiazine was obtained from the starting materials 4(6<italic>H</italic>)-amino-3-hydrazino-7-(2-thienyl)pyridazino[3,4-<italic>e</italic>][1,2,4]-triazine <bold>2</bold> and 9-amino-3-(2-thienyl)-2<italic>H</italic>,8<italic>H</italic>-pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-<italic>b</italic>][1,3,4]thiadiazine-8-carbonitrile <bold>12</bold>. Each of the starting compounds was subjected to a number of cyclization reactions to obtain a series of new heterocyclic fused systems, <bold>3</bold>–<bold>10</bold> and <bold>13</bold>–<bold>23</bold>, via bifunctional reagents. Some of the synthesized compounds were screened against three cell lines including HepG2, HCT-116 and MCF-7 to discover their anticancer activity. The synthesized compounds were characterized depending on their elemental analyses and spectral data.
- Publication
Molecules, 2018, Vol 23, Issue 5, p1024
- ISSN
1420-3049
- Publication type
Academic Journal
- DOI
10.3390/molecules23051024